BXM Wealth LLC Increases Stock Position in Amgen Inc. $AMGN

BXM Wealth LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 1,718.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 27,240 shares of the medical research company’s stock after purchasing an additional 25,742 shares during the period. BXM Wealth LLC’s holdings in Amgen were worth $8,916,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in AMGN. Brighton Jones LLC boosted its holdings in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC increased its stake in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the period. Schnieders Capital Management LLC. increased its stake in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares during the period. Kennedy Capital Management LLC lifted its position in shares of Amgen by 4.4% during the second quarter. Kennedy Capital Management LLC now owns 2,835 shares of the medical research company’s stock worth $792,000 after purchasing an additional 119 shares in the last quarter. Finally, Brown Advisory Inc. boosted its stake in shares of Amgen by 0.7% in the second quarter. Brown Advisory Inc. now owns 121,261 shares of the medical research company’s stock valued at $33,857,000 after purchasing an additional 812 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on AMGN. Guggenheim boosted their price target on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Argus lifted their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Price Performance

Shares of AMGN opened at $347.94 on Monday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The stock has a market cap of $187.56 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a fifty day moving average price of $363.65 and a 200 day moving average price of $333.18.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.